NASDAQ:PETS PetMed Express Q3 2026 Earnings Report $2.28 -0.02 (-0.87%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$2.30 +0.02 (+0.66%) As of 05/8/2026 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast PetMed Express EPS ResultsActual EPS-$0.50Consensus EPS -$0.06Beat/MissMissed by -$0.44One Year Ago EPSN/APetMed Express Revenue ResultsActual Revenue$40.66 millionExpected Revenue$54.04 millionBeat/MissMissed by -$13.38 millionYoY Revenue GrowthN/APetMed Express Announcement DetailsQuarterQ3 2026Date2/5/2026TimeAfter Market ClosesConference Call DateWednesday, February 4, 2026Conference Call Time6:00PM ETUpcoming EarningsPetMed Express' Q4 2026 earnings is estimated for Monday, May 11, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) PetMed Express Earnings HeadlinesPetMed Express, Inc.: PetMeds announces strategic partnership with Rural King to launch pet pharmacy offering across retail and digital channelsApril 23, 2026 | finanznachrichten.dePetMeds announces strategic partnership with Rural King to launch pet pharmacy offering across retail and digital channelsApril 22, 2026 | globenewswire.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 9 at 1:00 AM | Brownstone Research (Ad)Promising Penny Stocks To Consider In February 2026February 17, 2026 | finance.yahoo.comDiveroli Investment Group Files 13D in PetMed Express, Highlights Strategic Value, Asset Floor, and Multiple Takeover PathwaysFebruary 12, 2026 | finance.yahoo.comPetMed Express Shareholders Approve Directors, Pay and AuditorJanuary 26, 2026 | theglobeandmail.comSee More PetMed Express Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PetMed Express? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PetMed Express and other key companies, straight to your email. Email Address About PetMed ExpressPetMed Express (NASDAQ:PETS) operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations. Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications. The company launched its initial public offering in 2000 and has since developed an in‐house team of veterinarians and pharmacy professionals to review prescriptions and provide customer support. With a multi‐channel approach that includes online ordering, telephone service and direct mail catalogs, PetMed Express seeks to simplify the process of obtaining essential pet health products. PetMed Express primarily serves customers across the United States, with select offerings available in Canada. Its operations center around a fulfillment facility in Florida, supported by a network of third‐party carriers for nationwide delivery. The company is led by its founder and Chief Executive Officer, Marc Puleo, who oversees strategy and business development alongside a management team experienced in pharmaceutical distribution and e-commerce. PetMed Express continues to focus on expanding its product portfolio, enhancing digital capabilities and maintaining compliance with regulatory standards in veterinary pharmacy.View PetMed Express ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 05/04 - 05/08Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceHims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusAppLovin Pops After Earnings With Growth Catalysts in SightDutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality CheckThe AI Fear Around Datadog Stock May Have Been Completely WrongAmprius Technologies Ups the Voltage on Forward Outlook Upcoming Earnings Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
